ProCE Banner Activity

GFM Phase II Study of APR-246 Plus Azacitidine in TP53-Mutated MDS and AML

Slideset Download
Conference Coverage
Interim findings demonstrate that APR-246 yields a high CR rate when combined with azacitidine in patients with MDS or AML with TP53 mutations.

Released: December 19, 2019

Expiration: December 17, 2020

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Celgene

Dova Pharmaceuticals

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Karyopharm Therapeutics

Loxo Oncology subsidiary of Eli Lilly

Pharmacyclics an AbbVie Company